Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Public ClinicalTrials.gov record NCT01828697. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not known which dose is more efficacious in preventing recurrent venous thromboembolism in pregnancy. Patients enter the study and will be randomized as soon as a home test confirms pregnancy. LMWH will be administered until 6 weeks postpartum. Follow-up will continue until 3 months postpartum. Patients will be recruited by their treating physician, either an obstetrician or internist.
Study identification
- NCT ID
- NCT01828697
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,110 participants
Conditions and interventions
Conditions
Interventions
- Low dose nadroparin Drug
- Intermediate dose nadroparin Drug
- Low dose enoxaparin Drug
- Intermediate dose enoxaparin Drug
- Low dose dalteparin Drug
- Intermediate dose dalteparin Drug
- Fixed low dose tinzaparin Drug
- Intermediate dose tinzaparin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2013
- Primary completion
- Oct 30, 2021
- Completion
- Oct 30, 2021
- Last update posted
- May 25, 2022
2013 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Weill Cornell Medicine | NewYork-Presbyterian | New York | New York | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
Recently updated Deep Venous Thrombosis trials
Other public records listing Deep Venous Thrombosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07399977: Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism Recruiting
- NCT05701917: DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis Recruiting
- NCT04583878: FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease Active, not recruiting
- NCT06486181: Second Line Endovascular Treatment in Acute DVT Not yet recruiting
- NCT04924322: Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01828697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2022 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01828697 live on ClinicalTrials.gov.